On the Antithrombotic Effects of Doxazosin and Ramipril in Essential Hypertension
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 71
- 试验地点
- 1
- 主要终点
- Thrombin generation
研究概览
简要总结
Randomized double-blind parallel group study in patients with mild-to-moderate hypertension to evaluate the effects beyond the blood pressure lowering effect of treatment for 12 weeks with ramipril or doxazosin on hemostatic mechanisms and on endothelial function.
详细描述
This study aims to answer the following questions: 1) Does antihypertensive therapy with doxazosin exhibit antithrombotic effects in patients with essential hypertension? 2) Are the potential antithrombotic effects of doxazosin different to the effects of an ACE inhibitor? 3) Is there a relation between the antihypertensive effect and the antithrombotic effect of these antihypertensive agents?
The co-primary outcomes are changes in endothelial function assessed by flow mediated vasodilatation, and in haemostatic function measured by the generation of thrombin-antithrombin complex.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Primary mild-to-moderate hypertension
排除标准
- •Pregnancy and lactation
- •Recent (6 months) malignant disease or ongoing treatment for malignancy
- •No absolute indication or contraindication for any of the study drugs
研究组 & 干预措施
ACE inhibitor
Ramipril tablets 10 mg od for 12 weeks
干预措施: Ramipril (Drug)
Alpha receptor blocker
Doxazosin tablets 8 mg od for 12 weeks
干预措施: Doxazosin (Drug)
结局指标
主要结局
Thrombin generation
时间窗: 12 weeks
Thrombin-Antithrombin complex (TAT)
Endothelial function
时间窗: 12 weeks
Forearm post-ischemic flow mediated dilatation
次要结局
未报告次要终点
研究者
Thomas Kahan
Principal investigator, Professor
Karolinska Institutet